DUSA PHARMACEUTICALS RAISES $16.5 MM IN PRIMARY OFFERING.MISSISSAUGA, Ontario--(Health Wire)--December 15, 1995--DUSA Pharmaceuticals, Inc. (NASDAQ/NMS:DUSA DUSA Deputy Under Secretary of the Army DUSA Deakin University Student Association DUSA Dundee University Students' Association (Scotland) DUSA Designated Unclassified Subject Area ;TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :DSP (1) (Digital Signal Processor) A special-purpose CPU used for digital signal processing applications (see definition #2 below). It provides ultra-fast instruction sequences, such as shift and add, and multiply and add, which are commonly used in math-intensive ) accepted subscriptions for $16.5 million before expenses in a primary public offering of 3 million shares of common stock at $5.50 per share. The purchase of common stock was led by over 20 new institutional investors. Sunrise Securities Corp. placed all 3 million shares. Dr. Geoffrey Shulman, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. stated, "We are gratified grat·i·fy tr.v. grat·i·fied, grat·i·fy·ing, grat·i·fies 1. To please or satisfy: His achievement gratified his father. See Synonyms at please. 2. by the response we received from institutions and as a result of the offering, we will have over $20 million in current assets." DUSA Pharmaceuticals, Inc. is a development stage New Jersey company, with world-wide rights to ALA PDT, an experimental treatment for skin cancers, psoriasis and other skin and internal disorders, as well as endometrial ablation (non-surgical hysterectomy) and bladder cancer photodiagnosis. PDT treatment, a type of photodynamic therapy, combines the use of a pharmaceutical compound with exposure to light to induce a therapeutic effect. DUSA's clinical trial program has made it a world leader in the field of dermatological PDT. Copies of the prospectus may be obtained from Sunrise Securities Corp., 919 Third Avenue, 19th Floor, New York, NY 10022. CONTACT: DUSA Pharmaceuticals, Inc. Dr. Geoffrey Shulman 905/677-4554 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion